You are here

Oxypurinol Congestive Heart Failure Trial To Continue

Vancouver, Canada, July 9 2004, Cardiome Pharma Corp (NASD: CRME, TSX: COM) today announced that it’s independent Data Safety Monitoring Board (DSMB) has issued a recommendation to continue the phase 2 randomized controlled clinical trial, OPT-CHF, evaluating oxypurinol as an add-on treatment for class III-IV Congestive Heart Failure. The Cardiome DSMB unanimously voted to continue the study. The recommendation was based on the first planned safety analysis of data from the first subset of patients to complete the 24 week trial and a review of safety data from all patients currently enrolled in the trial.

Cardiome's DSMB is composed of independent medical experts who monitor and evaluate the safety of the clinical trial. In order to protect the integrity of the clinical trial, the company remains blinded to the data. OPT-CHF will enroll 400 patients. The Company expects enrollment to complete by the end of 2004, with results projected to be available in the third quarter of 2005.

About Oxypurinol
Cardiome’s lead drug in the congestive heart failure (CHF) area is oxypurinol, a xanthine oxidase inhibitor. CHF is the failure of the heart to pump blood at a rate sufficient to support the body’s needs. Oxypurinol sensitizes cardiac muscle cells to intracellular calcium, leading to increased cardiac oxygen-use efficiency. Cardiome believes that increasing the cardiac oxygen-use efficiency will improve the clinical outcomes for CHF patients. Oxypurinol is currently in a Phase 2 clinical trial that will evaluate the safety and effectiveness of oxypurinol in the treatment of patients with moderate to severe symptomatic CHF (rated by the New York Heart Association as class III-IV).

Source: Cardiome Pharma Corp

Recent Headlines

Averts Disease Worsening, Reduces Potential for Blindness
Risk May Remain for 6 Months After Treatment
FDA Removes Boxed Warning With Drug’s Fifth Approval
Overeager Use of Recommendations Creates Problems
Artificial Intelligence Enables Platform to Detect Amyloid PET Status
Kadcyla Cut Risk of Recurring Disease by Half Compared to Herceptin
May Lead to Personalized Treatment for Schizophrenia, Other Illnesses
First Medicines for Adults With Wild-type or Hereditary ATTR-CM